Get started
Author

Silu Yang

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
2024 · Miao-Zhen Qiu, Do-Youn Oh, et al. · BMJ · 345
PDF
Zika virus infection disrupts neurovascular development and results in postnatal microcephaly with brain damage
2016 · Qiang Shao, Stephanie Herrlinger, et al. · Development · 204
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
2020 · Lin Shen, Jun Guo, et al. · Journal for ImmunoTherapy of Cancer · 158
PDF
Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
2023 · Markus H. Moehler, Ken Kato, et al. · Journal of Clinical Oncology · 79
PDF
Ubiquitin Ligase Components Cullin4 and DDB1 Are Essential for DNA Methylation in Neurospora crassa
2009 · Yuanbiao Zhao, Ye Shen, et al. · Journal of Biological Chemistry · 65
MiR-302/367 regulate neural progenitor proliferation, differentiation timing, and survival in neurulation
2015 · Si-Lu Yang, Mei Yang, et al. · Developmental Biology · 43
Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab
2025 · Markus Moehler, Harry H. Yoon, et al. · Modern Pathology · 30
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma
2022 · Zhihao Lu, Silu Yang, et al. · Gastric Cancer · 16
PDF
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
2023 · Jayesh Desai, Peter Fong, et al. · British Journal of Cancer · 15
PDF
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
2025 · Markus Moehler, Do-Youn Oh, et al. · Advances in Therapy · 9
Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
2023 · Dingwei Ye, Jayesh Desai, et al. · Biomarker Research · 9
PDF
Multi-branch-feature fusion super-resolution network
2023 · Dong Li, Silu Yang, et al. · Digital Signal Processing · 8
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up
2025 · Marcia Cruz-Correa, Do-Youn Oh, et al. · Advances in Therapy · 7
PDF
Profiling the peripheral blood T cell receptor repertoires of gastric cancer patients
2022 · Mengyao Wang, Peng Gao, et al. · Frontiers in Immunology · 7
AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.
2021 · Lingying Wu, Peng-Hui Wang, et al. · Journal of Clinical Oncology · 7
Dynamic threshold P systems with delay on synapses for shortest path problems
2022 · Silu Yang, Dong Li, et al. · Theoretical Computer Science · 6
Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup.
2024 · Hendrik-Tobias Arkenau, Josep Tabernero, et al. · Journal of Clinical Oncology · 3
AdvanTIG-202: A phase 2 study investigating anti-T cell immunoglobulin and ITIM domain monoclonal antibody ociperlimab plus tislelizumab in patients with previously treated recurrent or metastatic cervical cancer (333)
2022 · Lingying Wu, Peng-Hui Wang, et al. · Gynecologic Oncology · 2
PDF
Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma.
2020 · Jianming Xu, Tianshu Liu, et al. · Journal of Clinical Oncology · 2
Inferring non‐synonymous single‐nucleotide polymorphisms‐disease associations via integration of multiple similarity networks
2014 · Jiaxin Wu, Silu Yang, et al. · IET Systems Biology · 1
U-shaped multilevel feature fusion super-resolution network
2024 · Silu Yang, Dong Li · International Conference on Control and Intelligent Robotics (ICCIR)
Abstract LB514: CD8 T cells and macrophage abundances associated with clinical benefit of tislelizumab in various tumor types
2022 · Wei Shen, Tengfei Liu, et al. · Cancer Research
Research on traditional Chinese medicine syndrome factors in cognitive disorder after apoplexy based on TCMISS
2016 · Si-Lu Yang, Chao-Lu-Men Han, et al. · IEEE International Conference on Bioinformatics and Biomedicine (BIBM)
Retraction Note to: DDB1 and Cul4 are necessary for gene silencing and heterochromatin formation at pericentromeric regions in Neurospora
2014 · Yingqiong Cao, Jicheng Wei, et al. · Protein & Cell
PDF
RETRACTED ARTICLE: DDB1 and Cul4 are necessary for gene silencing and heterochromatin formation at pericentromeric regions in Neurospora
2014 · Yingqiong Cao, Jicheng Wei, et al. · Protein & Cell
PDF
Works count: 25
Citation count: 1,016
H-index: 9
I10-index: 9
Year
Topic
Type